These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7511766)

  • 1. Nitric oxide may participate in V2 vasopressin-receptor-mediated renal vasodilation.
    Aki Y; Tamaki T; Kiyomoto H; He H; Yoshida H; Iwao H; Abe Y
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):331-6. PubMed ID: 7511766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arginine vasopressin produces renal vasodilation via V2 receptors in conscious dogs.
    Naitoh M; Suzuki H; Murakami M; Matsumoto A; Ichihara A; Nakamoto H; Yamamura Y; Saruta T
    Am J Physiol; 1993 Oct; 265(4 Pt 2):R934-42. PubMed ID: 8238468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pressor and renal vasoconstrictor effects of NG-nitro-L-arginine as affected by blockade of pressor mechanisms mediated by the sympathetic nervous system, angiotensin, prostanoids and vasopressin.
    Pucci ML; Lin L; Nasjletti A
    J Pharmacol Exp Ther; 1992 Apr; 261(1):240-5. PubMed ID: 1560371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional characterization of vasopressin V1 and V2 receptors in the rabbit renal cortical collecting duct.
    Yoshitomi K; Naruse M; Hanaoka K; Yamamura Y; Imai M; Kurokawa K
    Kidney Int Suppl; 1996 Jun; 55():S177-82. PubMed ID: 8743549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of arginine vasopressin and 1-desamino-8-D arginine vasopressin on forearm vasculature of healthy subjects and patients with a V2 receptor defect.
    van Lieburg AF; Knoers NV; Monnens LA; Smits P
    J Hypertens; 1995 Dec; 13(12 Pt 2):1695-700. PubMed ID: 8903635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide.
    Evora PR; Pearson PJ; Schaff HV
    Chest; 1993 Apr; 103(4):1241-5. PubMed ID: 8131474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of endothelium-derived relaxing factor in the in vivo renal vascular action of adenosine in dogs.
    Okumura M; Miura K; Yamashita Y; Yukimura T; Yamamoto K
    J Pharmacol Exp Ther; 1992 Mar; 260(3):1262-7. PubMed ID: 1545391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Through V2, not V1 receptor relating to endogenous opiate peptides, arginine vasopressin in periaqueductal gray regulates antinociception in the rat.
    Yang J; Chen JM; Liu WY; Song CY; Lin BC
    Regul Pept; 2006 Dec; 137(3):156-61. PubMed ID: 17011056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced renal vasoconstriction induced by vasopressin in SHR is mediated by V1 receptors.
    Feng JJ; Arendshorst WJ
    Am J Physiol; 1996 Aug; 271(2 Pt 2):F304-13. PubMed ID: 8770161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blocking effects of V1 (OPC-21268) and V2 (OPC-31260) antagonists on the negative inotropic response to vasopressin in isolated dog heart preparations.
    Furukawa Y; Takayama S; Ren LM; Sawaki S; Inoue Y; Chiba S
    J Pharmacol Exp Ther; 1992 Nov; 263(2):627-31. PubMed ID: 1331408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitric oxide mediates the inhibitory action of platelet-activating factor on angiotensin II-induced renal vasoconstriction, in vivo.
    Handa RK; Strandhoy JW
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1486-91. PubMed ID: 8667214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Nitric oxide in the renal and systemic vasodilatory responses to platelet-activating factor in the rat, in vivo.
    Handa RK; Strandhoy JW; Handa SE
    Kidney Blood Press Res; 2003; 26(3):165-75. PubMed ID: 12886044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations of renal hemodynamics in unilateral ureteral obstruction mediated by activation of endothelin receptor subtypes.
    Bhangdia DK; Gulmi FA; Chou SY; Mooppan UM; Kim H
    J Urol; 2003 Nov; 170(5):2057-62. PubMed ID: 14532853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of vasopressin in response to intrarenal infusions of alpha-2 adrenoceptor agonists.
    Blandford DE; Smyth DD
    J Pharmacol Exp Ther; 1990 Oct; 255(1):264-70. PubMed ID: 1976799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coronary vasoconstriction produced by vasopressin in anesthetized goats. Role of vasopressin V1 and V2 receptors and nitric oxide.
    Fernández N; García JL; García-Villalón AL; Monge L; Gómez B; Diéguez G
    Eur J Pharmacol; 1998 Jan; 342(2-3):225-33. PubMed ID: 9548390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. V2 receptor-mediated vasodilation in healthy humans.
    Tagawa T; Imaizumi T; Shiramoto M; Endo T; Hironaga K; Takeshita A
    J Cardiovasc Pharmacol; 1995 Mar; 25(3):387-92. PubMed ID: 7769802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of arginine vasopressin suppression of ovine fetal lung fluid secretion: lack of V2-receptor effect.
    Albuquerque CA; Nijland MJ; Ross MG
    J Matern Fetal Med; 1998; 7(4):177-82. PubMed ID: 9730483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arginine vasopressin-induced renal vasodilation mediated by nitric oxide.
    Rudichenko VM; Beierwaltes WH
    J Vasc Res; 1995; 32(2):100-5. PubMed ID: 7734655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasopressin-mediated forearm vasodilation in normal humans. Evidence for a vascular vasopressin V2 receptor.
    Hirsch AT; Dzau VJ; Majzoub JA; Creager MA
    J Clin Invest; 1989 Aug; 84(2):418-26. PubMed ID: 2527249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Withdrawal-induced antihypertensive effect of vasopressin: role of the L-arginine/nitric oxide pathway.
    Talom RT; McNeill JR
    Can J Physiol Pharmacol; 1997 Jul; 75(7):812-7. PubMed ID: 9315348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.